Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 3, 2018, Pages 565-570

  Tripodi, A ^a   Chantarangkul, V ^a   Legnani, C ^b   Testa, S ^c   Tosetto, A ^d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

anticoagulants; partial thromboplastin time; prothrombin time; quality control; thrombin time

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; ANTITHROMBIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ARTICLE; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; HUMAN; INTERLABORATORY VARIABILITY; INTERNATIONAL NORMALIZED RATIO; ITALY; MEASUREMENT; PARAMETERS; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY CONTROL; RELIABILITY; THROMBIN TIME; BLOOD; BLOOD CLOTTING TEST; CALIBRATION; CLINICAL LABORATORY SERVICE; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PROCEDURES; QUESTIONNAIRE; REPRODUCIBILITY; STANDARDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION TESTS; CALIBRATION; CLINICAL LABORATORY SERVICES; DABIGATRAN; HUMANS; INTERNATIONAL NORMALIZED RATIO; ITALY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; RIVAROXABAN; SURVEYS AND QUESTIONNAIRES; THROMBIN TIME;

EID: 85041139368     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13949     Document Type: Article

References (19)

1. Czuprynska J, Patel JP, Arya R. Current challenges and future prospects in oral anticoagulant therapy. Br J Haematol 2017; 178: 838–51.
2. Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013; 121: 4032–5.
3. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756–60.
4. Kitchen S, Gray E, Mackie I, Baglin T, Makris M; BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 2014; 166: 830–41.
5. Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, Moia M, Morelli B, Poli D, Steffan A, Testa S. Position paper on laboratory testing for patients on direct oral anticoagulants. Consensus document of SISET, FCSA, SIBioC and SIPMeL. Blood Transf 2017. https://doi.org/10.2450/2017.0124-17
6. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492–8.
7. Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jacquemin M, Jochmans K, Mullier F, Wijns W, China B, Vernelen K, Soumali MR. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. Int J Lab Hematol 2017; 39: 402–8.
8. Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jochmans K, Mullier F, Wijns W, Soumali MR, Coucke W, Vernelen K, Van de Walle P. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015; 113: 154–64.
9. Tripodi A, Chantarangkul V, Legnani C, Fronton R, Testa S. Discrepancy of the international normalized ratio observed in the external quality assessment survey: a cause for concern. J Thromb Haemost 2012; 10: 714–16.
10. Reijnierse GLA, van den Besselaar AMHP, Hermans J. Een nieuw verwerkingsprogramma van ingezonden uitslagen in het kader van externe kwaliteisbewaking. Ervaringen in 1988. Tijdschr NVKC 1989; 14: 131–6.
11. Weitz JI, Eikelboom JW. Urgent need to measure effects of direct oral anticoagulants. Circulation 2016; 134: 186–8.
12. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem 2013; 59: 353–62.
13. Tripodi A. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment. J Thromb Haemost 2017; 15: 1882–3.
14. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost 2016; 14: 1325–7.
15. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost 2016; 14: 2556–9.
16. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost 2016; 14: 2559–61.
17. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost 2017; 15: 202–4.
18. Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, Poli D, Palareti G. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 2016; 14: 2194–201.
19. Tripodi A, Padovan L, Testa S, Legnani C, Chantarangkul V, Scalambrino E, Ludovici E, Bassi L, Peyvandi F. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clin Chem Lab Med 2015; 53: 265–73.